| Literature DB >> 26763764 |
Paul Glue1, Gavin Cape2, Donna Tunnicliff2, Michelle Lockhart3, Fred Lam4, Andrew Gray1, Noelyn Hung1, C Tak Hung4, Sarah Harland1, Jane Devane5, John Howes5, Holger Weis5, Lawrence Friedhoff6.
Abstract
The aim of this study was to switch patients established on methadone opioid substitution therapy (OST) to morphine over 1 week. Subjects established on daily methadone OST (mean dose 60 mg/day) were switched to morphine slow-release capsules, dosed at 4× the previous total daily methadone dose, for 6 days, then given morphine syrup dosed q3h. All 27 subjects enrolled in this study completed the switch from methadone to morphine. Opioid withdrawal symptoms (OWS) peaked within 12-24 hours of starting morphine, and 24/27 subjects required higher daily morphine doses (mean 5.2× multiple). Pharmacokinetic evaluation showed that 91% of methadone was cleared during this time, with a mean elimination half-life of 59 hours. The most frequent treatment-emergent non-OWS adverse events were headache, nausea, constipation, and neck pain. The method described here appears to be a safe and acceptable approach to switch subjects from methadone to morphine.Entities:
Keywords: methadone; morphine; opioid substitution therapy; pharmacodynamics; pharmacokinetics; safety
Mesh:
Substances:
Year: 2016 PMID: 26763764 DOI: 10.1002/jcph.704
Source DB: PubMed Journal: J Clin Pharmacol ISSN: 0091-2700 Impact factor: 3.126